A study of SGLT2 inhibitors on levels of plasma atherogenesis biomarkers in diabetes
Naveenkumar Nallathambi, V Pratheep, C Adithyan, Yogesh Subramanian, P Balamanikandan · 2024
Read A study of SGLT2 inhibitors on levels of plasma atherogenesis biomarkers in diabetes by Naveenkumar Nallathambi, V Pratheep, C Adithyan, Yogesh Subramanian, P Balamanikandan (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11668460.txt.
Description
Naveenkumar Nallathambi and four co-authors published a 2024 study of diabetes drugs called SGLT2 inhibitors and their effect on blood markers of artery disease. Diabetes injures vessel walls through high sugar, feeding the plaque process behind heart attacks and strokes. The team followed 300 type 2 diabetes patients on these drugs for six months, tracking sugar control, lipids, and three computed atherogenic indices.
Triglycerides fell, protective HDL rose, and all three risk indices improved significantly. One odd note: LDL cholesterol rose slightly even as the composite indices improved. The authors conclude the drugs better the overall atherogenic profile beyond sugar control alone. They present the indices as cheap, non-invasive ways to watch cardiovascular risk in diabetes care.
Catalog record
| CREATOR | Naveenkumar Nallathambi, V Pratheep, C Adithyan, Yogesh Subramanian, P Balamanikandan |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |